Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 4:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 115 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo Inhalation Powder 2 Clear all
Withdrawn Phase 1 Interventional

Safety, Tolerability, and Efficacy of RLS103 in Subjects With Acute Anxiety Within Social Anxiety Disorder (SAD)

NCT05429788
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
Low dose RLS103, High dose RLS103, placebo inhaled dry powder
Drug
Lead sponsor
Receptor Life Sciences
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Los Angeles, California • Oceanside, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Sep 3, 2026, 4:58 AM EDT
Terminated Phase 3 Interventional Results available

A Twelve Month Long Term Safety Study to Evaluate the Safety of Albuterol in a Dry Powder Inhaler With Both Repeated and as Needed Dosing

NCT01218009
View directory record Official record
Conditions
Asthma
Interventions
Placebo Spiromax, Albuterol Spiromax
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
30
States / cities
Scottsdale, Arizona • Los Angeles, California • San Diego, California + 27 more
Source: ClinicalTrials.gov public record
Updated May 19, 2015 · Synced Sep 3, 2026, 4:58 AM EDT
Completed Phase 1 Interventional

A Study of the Safety and Pharmacokinetics of Levodopa Following Administration of CVT 301 (Levodopa Inhalation Powder) in Adults With Asthma

NCT02633007
View directory record Official record
Conditions
Asthma
Interventions
CVT-301 (levodopa inhalation powder), Carbidopa, Placebo
Drug · Other
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
25 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Daytona Beach, Florida • North Dartmouth, Massachusetts • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2016 · Synced Sep 3, 2026, 4:58 AM EDT
Completed Phase 2 Interventional Results available

A Dose-ranging Study to Evaluate Albuterol and Hydrofluoroalkane in Subjects Ages 12 and Older With Persistent Asthma

NCT01058863
View directory record Official record
Conditions
Asthma
Interventions
Albuterol Spiromax®, ProAir® HFA, Placebo Inhaler
Drug · Other
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
13
States / cities
Huntington Beach, California • Rolling Hills Est., California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 3, 2026, 4:58 AM EDT
Completed Phase 2 Interventional

Treating Exacerbations of Asthma With Oral Montelukast in Children

NCT05819541
View directory record Official record
Conditions
Status Asthmaticus
Interventions
Montelukast Oral Granules, Albuterol, Corticosteroid
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
4 Years to 12 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 3, 2026, 4:58 AM EDT
Completed Phase 4 Interventional Results available

Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2

NCT01662986
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium bromide, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
50
States / cities
Montgomery, Alabama • Flagstaff, Arizona • Glendale, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Sep 3, 2026, 4:58 AM EDT
Completed Phase 2 Interventional Results available

Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT02570165
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Batefenterol, Umeclidinium/ Vilanterol, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
9
States / cities
Hialeah, Florida • Baltimore, Maryland • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Sep 3, 2026, 4:58 AM EDT
Withdrawn Phase 3 Interventional

Bronchoprotective Effect of Arformoterol in Children With Exercise-Induced Bronchospasm (EIB)

NCT00662779
View directory record Official record
Conditions
Exercise-induced Bronchospasm
Interventions
arformoterol, formoterol, placebo
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
12 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Dec 10, 2015 · Synced Sep 3, 2026, 4:58 AM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administered Once Daily

NCT01147744
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Propionate 100mcg via ACCUHALER/DISKUS, GSK2190915 100mg, GSK2190915 10mg, GSK2190915 300mg, GSK2190915 30mg, Montelukast 10mg, Placebo GSK2190915 one tablet, Placebo montelukast, Placebo fluticasone propionate via ACCUHALER/DISKUS, Placebo GSK2190915 two tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older · Female only
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
22
States / cities
Birmingham, Alabama • Huntington Beach, California • Newport Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2017 · Synced Sep 3, 2026, 4:58 AM EDT
Completed Phase 2 Interventional Results available

A Dose-ranging Study of Fluticasone Furoate (FF)

NCT01563029
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Furoate, Fluticasone Propionate, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 11 Years
Enrollment
597 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
37
States / cities
Little Rock, Arkansas • Costa Mesa, California • Huntington Beach, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 3, 2026, 4:58 AM EDT
Completed Phase 3 Interventional Results available

A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT02152605
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
UMEC/VI, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
498 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
11
States / cities
Phoenix, Arizona • Upland, California • Clearwater, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Sep 3, 2026, 4:58 AM EDT
Terminated Phase 3 Interventional Results available

Trial in Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium.

NCT03460704
View directory record Official record
Conditions
Non Cystic Fibrosis Bronchiectasis
Interventions
CMS, Placebo
Drug · Other
Lead sponsor
Zambon SpA
Industry
Eligibility
18 Years and older
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
27
States / cities
Newport Beach, California • Palm Springs, California • Reseda, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Sep 3, 2026, 4:58 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients

NCT01746095
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Vancomycin hydrochloride inhalation powder, Placebo inhalation powder
Drug
Lead sponsor
Savara Inc.
Industry
Eligibility
12 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
38
States / cities
Mobile, Alabama • Little Rock, Arkansas • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Sep 3, 2026, 4:58 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Different Doses of Indacaterol

NCT01079130
View directory record Official record
Conditions
Asthma
Interventions
Indacaterol, Salmeterol, Placebo to Indacaterol, Placebo to Salmeterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
71
States / cities
Glendale, Arizona • Scottsdale, Arizona • Encinitas, California + 64 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2011 · Synced Sep 3, 2026, 4:58 AM EDT
Completed Phase 3 Interventional Results available

A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler in Pediatric Asthmatics

NCT02126839
View directory record Official record
Conditions
Asthma
Interventions
Albuterol MDPI, Placebo, ProAir HFA inhaler
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
51
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Alaska + 45 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 3, 2026, 4:58 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma

NCT00079937
View directory record Official record
Conditions
Asthma
Interventions
Omalizumab, Placebo, Fluticasone
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 11 Years
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
56
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Huntington Beach, California + 48 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2012 · Synced Sep 3, 2026, 4:58 AM EDT
Completed Phase 3 Interventional Results available

Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2

NCT02119286
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
FF, VI, UMEC, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
620 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
14
States / cities
Mobile, Alabama • Phoenix, Arizona • Huntington Beach, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Sep 3, 2026, 4:58 AM EDT
Completed No phase listed Observational

ELLIPTA™ vs. MDI Inhaler Preference Study, in Adult Subjects With Asthma

NCT02135718
View directory record Official record
Conditions
Asthma
Interventions
ELLIPTA inhaler, Placebo Inhalation Aerosol (MDI)
Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
15
States / cities
Huntington Beach, California • Newport Beach, California • Vista, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2016 · Synced Sep 3, 2026, 4:58 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01817764
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Umeclidinium/vilanterol, Fluticasone propionate/salmeterol, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
707 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
9
States / cities
Jasper, Alabama • Phoenix, Arizona • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Sep 3, 2026, 4:58 AM EDT
Completed Phase 2 Interventional Results available

Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children

NCT01573767
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone propionate 100mcg, Placebo, Vilanterol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 11 Years
Enrollment
463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
34
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2017 · Synced Sep 3, 2026, 4:58 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF Episodes

NCT01777555
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
CVT-301, Placebo
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
30 Years to 80 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
13
States / cities
Little Rock, Arkansas • Boca Raton, Florida • Port Charlotte, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Sep 3, 2026, 4:58 AM EDT
Terminated Phase 2 Interventional

Study in Adult Asthmatic Patients With Allergic Bronchopulmonary Aspergillosis

NCT03960606
View directory record Official record
Conditions
Allergic Bronchopulmonary Aspergillosis
Interventions
PUR1900, Placebo
Combination Product
Lead sponsor
Pulmatrix Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
9
States / cities
Denver, Colorado • New Haven, Connecticut • Hialeah, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2021 · Synced Sep 3, 2026, 4:58 AM EDT
Completed Phase 2 Interventional

PT005 MDI Dose Ranging Versus Foradil Aerolizer Study

NCT01349868
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
PT005 MDI, Formoterol Fumarate 12 μg (Foradil® Aerolizer®), Formoterol Fumarate 24 μg (Foradil® Aerolizer®), Placebo MDI
Drug · Other
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
3
States / cities
Clearwater, Florida • Tampa, Florida • Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 11, 2012 · Synced Sep 3, 2026, 4:58 AM EDT
Completed Phase 4 Interventional Results available

Study of the Ease of Use and Correct Use of Placebo ELLIPTA® Inhaler in Subjects With Asthma

NCT02586506
View directory record Official record
Conditions
Asthma
Interventions
Placebo ELLIPTA inhaler, Questionnaire
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
15
States / cities
Mobile, Alabama • Huntington Beach, California • Aventura, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2017 · Synced Sep 3, 2026, 4:58 AM EDT